A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR) (2020)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s13014-020-01593-5
PubMed Identifier: 32532291
Publication URI: http://europepmc.org/abstract/MED/32532291
Type: Journal Article/Review
Parent Publication: Radiation Oncology
Issue: 1
ISSN: 1748-717X